Ledviclear

Discount 5.00 USD
BRAND :  LEDVICLEAR PRICE :  275$ STRENGTH : 90 MG LEDIPASVIR AND 400 MG SOFOSBUVIR ACTIVE :  LEDVICLEAR-SOFOSBUVIR-400MG-LEDIPASVIR-90MG COMPANY NAME :  ABBOTT TABLETS... read more

275.00 USD
280.00
- +
Share

Drug profile:

Ledviclear tablets are an anti-viral agent.

Ledviclear tablets which have procured by a patient only with a prescription

Ledviclear tablets fixed-dose combination contains sofosbuvir and ledipasvir

Trade name: Ledviclear

Active components: sofosbuvir & ledipasvir

Strength of the components: 400mg & 90mg respectively

Mfg: Abbott 

Package: 28 tablets in a container

Category: Anti-cancer agent.


Ledviclear Prescribing Information:

Ledviclear is a very effective drug, involves the treatment of chronic hepatitis C viral infection.

Ledviclear is a single dose medicine, used alone or in combination with other anti-viral medicines in a chronic condition.

Ledviclear, used by the patients having a valid prescription.


Ledviclear Mechanism of Action:

Ledviclear has two eminent compounds like;

Sofosbuvir & ledipasvir

Ledviclear is directly acting anti-viral drug, exhibits its activity by inhibiting the viral replication

Ledipasvir: exhibits its action by intercedes with NS5A activity which is important for viral multiply, secretion and colony of HCV virions. Due to effect of ledipasvir, NS5A inhibitor causes eradicate viral growth

Sofosbuvir: Generally it is anti-hepaciviral associated with NS5B polymerase inhibitor. This polymerase enzyme is responsible for viral proliferation, by interfering with these enzymes causes stoppage of viral reproduction acts as a chain terminator.


Absorption:

The absorption of Ledviclear occurs rapidly, the peak plasma concentration of sofosbuvir 0.8 to 1 hour, ledipasvir is 4 to 4.5 hours; and GS-331007 3.5 to 4 hours.


Distribution:

Ledviclear should be administered with or without food; the human plasma protein bound of Ledviclear occurs as >99.8%; sofosbuvir 61 to 65%.

The metabolite of sofosbuvir GS-331007 has minimal plasma protein bounding capability.


Metabolism:

Ledviclear tablet contains ledipasvir which is not metabolized hepatically and is excreted through feces as an unchanged form. Sofosbuvir metabolized to pharmacologically active form GS-461203.


Elimination:

Ledviclear Excretion occurs through feces and urine

Sofosbuvir:

Urine: 80%, feces: 14%, exhaled air: 3.5%

Ledipasvir:

99% in feces & 1% in urine as an unchanged.


When to take Ledviclear tablets:

Ledviclear tablets should be taken as a once a day, with or without a meal

Ledviclear is a prescription medicine; care should be taken to avoid the self-medication problems

Ledviclear used either alone or with a combination.


Dosage Regimens

In adults:

The recommended dose of Ledviclear tablets in adults are;

One tablet 90mg/400mg to be taken as a single dose.


Patients acquired without cirrhosis or with compensated cirrhosis:

Ledviclear should be taken as a single dose orally for 12 weeks.


Therapy-experienced without cirrhosis:

Ledviclear should be taken as once a day for 12 weeks.


Therapy-experienced with compensated cirrhosis:

Ledviclear should be taken as a single dose for 24 weeks alone or in combination with ribavirin.


In decompensated cirrhosis:

Ledviclear combined with weight-based ribavirin followed for 12 weeks

Ribavirin dosage regimen:

<75kg: 1000mg per day

≥75kg: 1200mg per day


In Genotype I or IV:

Spontaneous therapy and therapy competent without cirrhosis or with compensated cirrhosis:

Ledviclear with ribavirin taken for 12 weeks as a single dose.


In genotype IV, V or VI:

Therapy-experienced and therapy naïve without cirrhosis or with compensated cirrhosis:

Ledviclear should be taken as a single dose for 12 weeks.


Dosage adjustment:

In renal and hepatic impairment patients, mild or moderate conditions, on dosage adjustments required

In decompensated condition, safety and efficacy have not been established.


In pediatric:

Used for HCV infection:

Duration of therapy:


Genotype IV, V or VI:

Therapy naïve and experienced without cirrhosis or with compensated cirrhosis:

Ledviclear followed for 12 weeks as a single dose.


Genotype I:

Therapy naïve with compensated cirrhosis or without cirrhosis:

Ledviclear recommended for 12 weeks as a single dose.


Therapy-experienced without cirrhosis:

Ledviclear took orally as a single dose for 12 weeks.


Therapy naïve and experienced without cirrhosis or with compensated cirrhosis:

Ledviclear took for 24 weeks as a single dose.


Ledviclear is majorly indicated in pediatric patients with the age of 12 or older or weight of 35kg

<12 years or <35kg: the safety and efficacy has not been established

≥12 years or ≥35kg: one tablet to be taken as a single dose.


Ledviclear Called side effects:

Adverse effects in cirrhosis condition;

Asthenia, headache, fatigue, Myalgia, dyspnea, dizziness and irritability

Elevation of bilirubin levels

Elevation of lipase level

Elevation of creatine kinase levels

In cardiac: bradycardia, cardiac arrest

Skin: angioedema and rashes

Serious bradycardia occurs

While combining with ribavirin, related problems occurs

Common side effects;

Headache

Fatigue

Nausea

Diarrhea

Insomnia


Drug Interaction:

Ledviclear concomitant with other drugs likes;

Ledviclear With antacids: like proton pump inhibitors, H2 receptor antagonist causes reduce effect of concentration of ledipasvir

Ledipasvir: Drug transporter P-gp inhibitors and breast cancer resistance protein inhibitor, while concomitant with Sofosbuvir and ledipasvir may causes increase the intestinal absorption of these substrates

Ledviclear with HMG CoA reductase: increase the effect of concentration of these lipid mimic drugs

Ledviclear With amiodarone: serious bradycardia occurs

Ledviclear With digoxin: increase the effect of concentration of digoxin

Ledviclear With anti-convulsants: reduce the effect of concentration of Sofosbuvir and ledipasvir

Ledviclear With anti-mycobacterials: reduce the effect of concentration of Sofosbuvir and ledipasvir.


Food -Drug Interactions:

Food-drug interaction in Ledviclear tablets; food does not interfere with the activity of Ledviclear.

Herbal product like st. Johns wort combined with Ledviclear may cause loss of effect of concentration of Ledviclear.


Possible Contraindications:

Ledviclear tablets are contraindicated;

Hypersensitivity reactions occur

Renal and hepatic impairment patients

While combining with ribavirin contraindicated to pregnancy conditions.


Safety Measures:

Exposed to adverse effects due to concomitant with ribavirin.

Risk of the reaction of HBV infection to HCV/HBV co-infected patients.

Care was taken in hepatic and renal impairment patients.

The possibility of symptomatic bradycardia occurs during combination with ribavirin.

Risk of loss of therapeutic effect because of combination with P-gp inducers.


Pregnancy and Lactation:

Ledviclear with ribavirin pregnancy category: X.

Ribavirin causes fetal death.

Ledviclear pregnancy category: B1.

Ledviclear is safe to use in case of monotherapy (used alone).

Breastfeeding is not recommended for the patients who are getting ribavirin.


Storage and Handling:

Ledviclear tablets container should be stored at room temperature below 30oC

Ledviclear Container should be kept away from moisture, heat, and light.


Missed Dose:

Ledviclear tablets are prescription use, before taking the tablet patient must advise by a physician for avoiding self-medication.

If the patient fails to take the dose Ledviclear, must consult with a medical practitioner and administered the missed dose as soon as possible within the time.

Otherwise, the missed dose should be skipped and maintain the regular dosing schedule.

Do not take an overdose.


Overdosage:

The maximum dose of Ledviclear (Sofosbuvir and ledipasvir) was 1200mg and 120mg twice daily for 10days.

No special antidote is recommended for overdosage of ledipasvir and Sofosbuvir.

If overdosage of both drugs, patients should be examined for confirmation of toxicity.

Hemodialysis is suitable for elimination of ledipasvir hence; ledipasvir is largely bound to plasma protein and also helps to expel the dominant circulating metabolite of Sofosbuvir GS-331007 with a range of 53%.

Other precaution: in case of overdosage, contact poison information center as soon as possible.

    No comments yet
Write a comment
Your name
Your name
Captcha

Sale of day

Choice of buyers. Only popular options!Choice of buyers.
Only popular options!

view all
Abbott
Biocon
Cipla
Dr. Reddy’s
Eisai
Emcure
Hetero
Intas
MSD
Mylan
Natco
Novartis
Strides
Zydus
  • Children born with HIV
    Children born with HIV
    Children born with HIV accessing treatment, have no significant difference in their movement skills, social interaction, language skills or practical reasoning at age five compared to HIV-negative children, according to new research....